Toggle navigation
Login
Toggle navigation
JavaScript is disabled for your browser. Some features of this site may not work without it.
Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers
QMRO Home
Barts Cancer Institute
Centre for Molecular Oncology
Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers
QMRO Home
Barts Cancer Institute
Centre for Molecular Oncology
Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers
Browse
All of QMRO
Communities & Collections
By Issue Date
Authors
Titles
Subjects
This Collection
By Issue Date
Authors
Titles
Subjects
Administrators only
Login
Statistics
Most Popular Items
Statistics by Country
Most Popular Authors
Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers
View/
Open
Published version (2.091Mb)
Volume
10
Pagination
1943253 - ?
Publisher
Taylor & Francis
DOI
10.1080/2162402x.2021.1943253
Journal
OncoImmunology
Issue
1
ISSN
2162-4011
Metadata
Show full item record
Authors
Chang, K-Y; Chiang, N-J; Wu, S-Y; Yen, C-J; Chen, S-H; Yeh, Y-M; Li, C-F; Feng, X; Wu, K; Johnston, A
URI
https://qmro.qmul.ac.uk/xmlui/handle/123456789/73337
Collections
Centre for Molecular Oncology
[272]
Licence information
Creative Commons Attribution-NonCommercial License
Copyright statements
© 2021 The Author(s).
Except where otherwise noted, this item's license is described as Creative Commons Attribution-NonCommercial License